Developing a new HIV vaccine using nanoparticles and engineered mRNA
Official title: Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery
Funded at Icahn School of Medicine at Mount Sinai · NIH-10979148 · Data updated 2026-11-12
This study is working on a new HIV vaccine that uses tiny particles to boost the immune system's response, aiming to give people better protection against HIV infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 9, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $729,905 |
| NIH project number | 5R01AI174902-03 |
| Project ID | NIH-10979148 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for HIV infection or those who are currently living with HIV.
✕Less likely to help
Patients who are not at risk for HIV or who have already been effectively treated and are not seeking vaccination may not benefit from this research.
What this research studies
This research focuses on creating a more effective vaccine for HIV by integrating nanoparticles derived from adjuvants with engineered mRNA. The approach aims to enhance the immune response by stimulating specific receptors in the immune system, which can lead to better protection against HIV. By using advanced techniques to improve the delivery of vaccine components and the design of immunogens, the research seeks to overcome existing challenges in HIV vaccine development. Patients may benefit from a more effective vaccine that could provide better protection against HIV infections.
Why it matters
Potential benefit: If successful, this research could lead to the development of a highly effective HIV vaccine, significantly reducing the incidence of HIV infections.
How similar studies have gone: Previous research has shown promise in using similar approaches to enhance vaccine efficacy, indicating potential for success in this novel application.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Dong, Yizhou — Icahn School of Medicine at Mount Sinai
- Study coordinator: Dong, Yizhou
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genetically Validated PCOS Subtypes for Better Diagnosis and Risk Stratification
Aimed at women with polycystic ovary syndrome (PCOS), this project uses genetic data and patient characteristics to define distinct PCOS subtypes and improve how we diagnose and estimate risk.
-
Closed-loop control of interneuron timing to influence seizures and memory in epilepsy
A study tests a brain-quieting system that uses light to precisely time certain brain cells in epilepsy-prone mice to see if this can lessen seizures and improve memory.
-
Understanding why some brain regions and cells accumulate tau in Alzheimer’s and related diseases
Researchers are studying why certain brain areas and neuron types accumulate tau protein in Alzheimer’s and related conditions, and how this leads to brain changes and symptoms.
-
Improving blood flow after stroke by breaking down NETs
Aims to see if breaking down neutrophil extracellular traps (NETs) after an ischemic stroke can improve blood flow and reduce brain injury in patients.
-
Aging and brain injury connection: learning how late-life TBI relates to Alzheimer’s and related dementias
This grant looks at whether traumatic brain injuries in people 65 and older are linked to Alzheimer’s disease and related dementias, using a large, harmonized set of long-term aging studies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.